Products Grants Program News Today

/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results...

In a break with past precedent, last year’s Food and Drug Administration (FDA) user fee reauthorization legislation did not contain significant FDA policy changes. Although the Senate...

These measures follow the successful passage of H.R. 6833 in October, which included a five-year reauthorization of critical FDA user-fee programs that help ensure rare disease patients gain timely access to essential therapies and diagnostic tools.

The fund will back clinical trials, natural history studies, and regulatory science tools that will give the FDA a greater understanding of the ways that rare diseases can be treated.

SILVER SPRING, Md., Oct. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38

Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.

WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has awarded 19 new grants and two new contracts totaling more than $38 million in funding mainly to develop medical products to treat

/PRNewswire/ -- Today, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38 million in...

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb's Orencia has received approval from the U.S. Food and Drug Administration for prophylaxis or prevention of acute graft versus host disease or aGVHD.This

/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease...